NO20026152L - Kombinasjoner og preparater som interfererer med VEGF/VFGF-reseptor- og angiopoietin/Tie reseptor-funksjon og deres anvendelse - Google Patents
Kombinasjoner og preparater som interfererer med VEGF/VFGF-reseptor- og angiopoietin/Tie reseptor-funksjon og deres anvendelseInfo
- Publication number
- NO20026152L NO20026152L NO20026152A NO20026152A NO20026152L NO 20026152 L NO20026152 L NO 20026152L NO 20026152 A NO20026152 A NO 20026152A NO 20026152 A NO20026152 A NO 20026152A NO 20026152 L NO20026152 L NO 20026152L
- Authority
- NO
- Norway
- Prior art keywords
- vegf
- receptor
- angiopoietin
- interfering
- vfgf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00250194A EP1166798A1 (de) | 2000-06-23 | 2000-06-23 | Zusammensetzungen die interferieren mit VEGF/VEGF und Angiopoietin/Tie Rezeptor-Funktionen |
EP00250214A EP1166799A1 (de) | 2000-06-28 | 2000-06-28 | Zusammensetzungen die interferieren mit VEGF/VEGF und Angiopoietin/Tie Rezeptor-Funktionen |
PCT/EP2001/006976 WO2001097850A2 (en) | 2000-06-23 | 2001-06-20 | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20026152D0 NO20026152D0 (no) | 2002-12-20 |
NO20026152L true NO20026152L (no) | 2003-02-21 |
Family
ID=26072945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20026152A NO20026152L (no) | 2000-06-23 | 2002-12-20 | Kombinasjoner og preparater som interfererer med VEGF/VFGF-reseptor- og angiopoietin/Tie reseptor-funksjon og deres anvendelse |
Country Status (29)
Country | Link |
---|---|
US (2) | US20030055006A1 (de) |
EP (2) | EP1292335B1 (de) |
JP (1) | JP2003535910A (de) |
KR (2) | KR20080068151A (de) |
CN (1) | CN1479629A (de) |
AT (1) | ATE363291T1 (de) |
AU (1) | AU784231B2 (de) |
BG (1) | BG107396A (de) |
BR (1) | BR0111861A (de) |
CA (1) | CA2411236A1 (de) |
CY (1) | CY1107717T1 (de) |
CZ (1) | CZ2003187A3 (de) |
DE (1) | DE60128685T2 (de) |
DK (1) | DK1292335T3 (de) |
EE (1) | EE200200706A (de) |
ES (1) | ES2287152T3 (de) |
HR (1) | HRP20030041A2 (de) |
HU (1) | HUP0302779A3 (de) |
IL (1) | IL152794A0 (de) |
ME (1) | MEP13708A (de) |
MX (1) | MXPA02011897A (de) |
NO (1) | NO20026152L (de) |
NZ (1) | NZ536196A (de) |
PL (1) | PL359653A1 (de) |
PT (1) | PT1292335E (de) |
RS (1) | RS50249B (de) |
RU (1) | RU2292221C2 (de) |
SK (1) | SK542003A3 (de) |
WO (1) | WO2001097850A2 (de) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
US7109167B2 (en) | 2000-06-02 | 2006-09-19 | Bracco International B.V. | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
WO2005078097A2 (en) | 2004-02-10 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2003004529A2 (en) * | 2001-07-02 | 2003-01-16 | Licentia Ltd. | Ephrin-tie receptor materials and methods |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (de) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | Durch rna-interferenz vermittelte inhibierung von map-kinase-genen |
US7666979B2 (en) | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
US7261876B2 (en) * | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7985402B2 (en) | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US20050250700A1 (en) * | 2002-03-01 | 2005-11-10 | Sato Aaron K | KDR and VEGF/KDR binding peptides |
US20060228706A1 (en) * | 2002-06-04 | 2006-10-12 | Metabolex, Inc. | Methods of diagnosing and treating diabetes and insulin resistance |
GB0222276D0 (en) * | 2002-09-25 | 2002-10-30 | Inst Of Molecul & Cell Biology | Methods |
CA2517939C (en) | 2003-03-03 | 2015-11-24 | Dyax Corp. | Peptides that specifically bind hgf receptor (cmet) and uses thereof |
WO2004094606A2 (en) * | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2 |
CA2535171A1 (en) * | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
US7871610B2 (en) * | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
WO2005087808A2 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
KR101254815B1 (ko) | 2004-07-20 | 2013-09-03 | 제넨테크, 인크. | 안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도 |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
US20060105663A1 (en) * | 2004-10-04 | 2006-05-18 | Stefan Greulich | Polymer assemblies with decorative surfaces |
WO2007042504A2 (fr) | 2005-10-07 | 2007-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
CN101370519B (zh) | 2005-12-15 | 2013-07-24 | 阿斯利康(瑞典)有限公司 | 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合 |
KR101589391B1 (ko) | 2006-01-05 | 2016-01-29 | 제넨테크, 인크. | 항-ephb4 항체 및 그의 사용 방법 |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
AU2007233237A1 (en) * | 2006-03-29 | 2007-10-11 | Genentech, Inc. | Diagnostics and treatments for tumors |
MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
JP2009539870A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 血管発生の調節ための組成物および方法 |
EP2032604A2 (de) * | 2006-06-06 | 2009-03-11 | Genentech, Inc. | Anti-dll4-antikörper sowie verfahren zu deren verwendung |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20080213253A1 (en) * | 2007-01-12 | 2008-09-04 | Dyax Corp. | Combination therapy for the treatment of cancer |
WO2008091222A1 (en) * | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
US10259860B2 (en) * | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
CA2703099A1 (en) * | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Activin receptor-like kinase-i compositions and methods of use |
AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
CA2727792C (en) | 2008-03-14 | 2017-07-25 | Obschestvo S Ogranichennoi Otvetstvennostyu "Initium-Pharm" | Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action |
US20100055099A1 (en) * | 2008-08-29 | 2010-03-04 | Ellen Filvaroff | Diagnostics and Treatments for VEGF-Independent Tumors |
AU2009303526B2 (en) | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2010054010A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
KR101426125B1 (ko) | 2009-07-06 | 2014-08-06 | 에르피오 세러퓨틱스 인코포레이티드 | 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법 |
US20110027275A1 (en) * | 2009-07-31 | 2011-02-03 | Napoleone Ferrara | Inhibition of tumor metastasis |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
EP2496600A1 (de) | 2009-11-04 | 2012-09-12 | Fabrus LLC | Verfahren zur optimierung von antikörpern auf der basis von affinitätsreifung |
EP2509626B1 (de) | 2009-12-11 | 2016-02-10 | F.Hoffmann-La Roche Ag | Anti-vegf-c-antikörper und verfahren zu ihrer verwendung |
MY161868A (en) | 2009-12-23 | 2017-05-15 | Genentech Inc | Anti-bv8 antibodies and uses thereof |
DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
MX2013005388A (es) | 2010-11-15 | 2013-11-04 | Five Prime Therapeutics Inc | Terapias de combinadas de dominio extracelular del receptor del factor de crecimiento de fibroblastos 1 (fgfr1). |
FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
EP2699590B8 (de) | 2011-04-20 | 2019-04-17 | Acceleron Pharma Inc. | Endoglinpolypeptide und ihre verwendung |
CN102250248A (zh) * | 2011-06-15 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗vegf/ang2双特异性抗体及其应用 |
CA2842481A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
US10316105B2 (en) | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
CN103874709B (zh) | 2011-08-19 | 2016-12-21 | 瑞泽恩制药公司 | 抗tie2抗体及其用途 |
FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
AU2012323849B2 (en) | 2011-10-13 | 2017-04-20 | EyePoint Pharmaceuticals, Inc. | Treatment of ocular disease |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
FR3001154B1 (fr) | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
US20150202260A1 (en) | 2013-10-25 | 2015-07-23 | Acceleron Pharma, Inc. | Endoglin peptides to treat fibrotic diseases |
WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
AU2017299581B2 (en) | 2016-07-20 | 2024-05-23 | EyePoint Pharmaceuticals, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-β) |
IL264962B1 (en) | 2016-08-23 | 2024-05-01 | Medimmune Ltd | Antibodies against VEGF-A and against ANG2 and their uses |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
-
2001
- 2001-06-20 IL IL15279401A patent/IL152794A0/xx unknown
- 2001-06-20 DK DK01965012T patent/DK1292335T3/da active
- 2001-06-20 PL PL01359653A patent/PL359653A1/xx unknown
- 2001-06-20 EP EP01965012A patent/EP1292335B1/de not_active Expired - Lifetime
- 2001-06-20 AT AT01965012T patent/ATE363291T1/de not_active IP Right Cessation
- 2001-06-20 EP EP05090011A patent/EP1586333A2/de not_active Withdrawn
- 2001-06-20 ME MEP-137/08A patent/MEP13708A/xx unknown
- 2001-06-20 SK SK54-2003A patent/SK542003A3/sk unknown
- 2001-06-20 BR BR0111861-7A patent/BR0111861A/pt not_active IP Right Cessation
- 2001-06-20 WO PCT/EP2001/006976 patent/WO2001097850A2/en active IP Right Grant
- 2001-06-20 RU RU2003100502/15A patent/RU2292221C2/ru not_active IP Right Cessation
- 2001-06-20 MX MXPA02011897A patent/MXPA02011897A/es active IP Right Grant
- 2001-06-20 PT PT01965012T patent/PT1292335E/pt unknown
- 2001-06-20 CN CNA018115837A patent/CN1479629A/zh active Pending
- 2001-06-20 KR KR1020087016915A patent/KR20080068151A/ko not_active Application Discontinuation
- 2001-06-20 ES ES01965012T patent/ES2287152T3/es not_active Expired - Lifetime
- 2001-06-20 RS YU97202A patent/RS50249B/sr unknown
- 2001-06-20 CA CA002411236A patent/CA2411236A1/en not_active Abandoned
- 2001-06-20 AU AU85766/01A patent/AU784231B2/en not_active Ceased
- 2001-06-20 HU HU0302779A patent/HUP0302779A3/hu unknown
- 2001-06-20 KR KR1020027017482A patent/KR20030036238A/ko not_active Application Discontinuation
- 2001-06-20 DE DE60128685T patent/DE60128685T2/de not_active Expired - Fee Related
- 2001-06-20 CZ CZ2003187A patent/CZ2003187A3/cs unknown
- 2001-06-20 JP JP2002503334A patent/JP2003535910A/ja active Pending
- 2001-06-20 NZ NZ536196A patent/NZ536196A/en unknown
- 2001-06-20 EE EEP200200706A patent/EE200200706A/xx unknown
- 2001-06-25 US US09/887,527 patent/US20030055006A1/en not_active Abandoned
-
2002
- 2002-12-17 BG BG107396A patent/BG107396A/bg unknown
- 2002-12-20 NO NO20026152A patent/NO20026152L/no not_active Application Discontinuation
-
2003
- 2003-01-23 HR HR20030041A patent/HRP20030041A2/hr not_active Application Discontinuation
-
2004
- 2004-03-10 US US10/796,174 patent/US20040147449A1/en not_active Abandoned
-
2007
- 2007-08-14 CY CY20071101085T patent/CY1107717T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20026152L (no) | Kombinasjoner og preparater som interfererer med VEGF/VFGF-reseptor- og angiopoietin/Tie reseptor-funksjon og deres anvendelse | |
DK1459749T3 (da) | (S,S)-reboxetin til behandling af inkontinens | |
DK2412368T3 (da) | Sammensætning til behandling af ar | |
DE60025010D1 (de) | Chirurgisches system zur befestigung von gewebe | |
EE200300239A (et) | Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks | |
BR0014560B1 (pt) | uso de uma composiÇço de tratamento de tecidos. | |
EE200300165A (et) | Fenofibraadi ja koensüüm Q10 kombinatsioon endoteeli düsfunktsiooni ravimiseks | |
DK1183269T3 (da) | Svækkede mikroorganismer til behandlingen af infektion | |
NO20021964L (no) | Biologisk fluidbehandling | |
DE60136909D1 (de) | Arzneimittel mit anemonin als aktivum zur behandlung von aseptischer inflammation | |
DE60220220D1 (de) | Blutbehandlungssystem | |
DK1331940T3 (da) | Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2 | |
DK1231915T3 (da) | Anvendelse af pleuromutilinderivater til transdermal behandling af bakterielle sygdomme | |
PT1220858E (pt) | Oxazinoquinolonas uteis para o tratamento de infeccoes virais | |
EA200200853A1 (ru) | Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака | |
IT1317070B1 (it) | Pilastro di guarigione per immobilizzazione intrachirurgica diimpianti dentali per carico immediato. | |
AP2009004857A0 (en) | Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof | |
IT1320192B1 (it) | Composizione terapeutica per la cura della psoriasi. | |
FR2813787B1 (fr) | Attelle pour la chirurgie des voies lacrymales | |
DK0980251T3 (da) | Vævsfaktor til påvirkning af blodkardannelse | |
BR0007395B1 (pt) | compostos de s-nitrosotióis como agentes para o tratamento de disfunções circulatórias. | |
ITMI20000611A0 (it) | Stent perfezionato per la dilatazione di vasi sanguigni | |
SE9904334L (sv) | Biologiskt kontrollmedel | |
ES1047697Y (es) | Nuevo sistema de implantes dentales funcionales. | |
ES1043878Y (es) | Nuevo soporte o plataforma de porta-calendario. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |